Oncology Industry
Insights & Trends

April 29, 2020

Slice & Dice the Data

The COVID-19 WORLDWIDE CLINICAL DEVELOPMENT Dashboard, powered by #Kognitic, is an integrated tool which places the power to deep-dive into #Covid19data in the hands of the […]
April 27, 2020

Kognitic Makes a Splash in the Covid-19 Data Stream

Today, #Kognitic released our #Covid_19 dashboard which leverages #machinelearning to capture data from Covid-19 #clinicaltrials in real-time. This portal integrates industry data to provide high-level insights […]
April 27, 2020

Vaccines vs Treatment: Live Analysis of COVID-19 Trials

Today, #Kognitic opens public access to our insight-driven, live dashboard to keep abreast of all the #Covid19 clinical developments! Updated daily with data sourced directly from […]
April 26, 2020

Behind-the-Scenes Heroes of COVID-19

#Kognitic would like to take a moment to thank the #researchers who are working unremittingly to find a #cure for #covid19. These #scientists are working around […]
April 21, 2020

Kognitic Launches Innovative Map Feature to its Clinical Trial Intelligence Platform

Kognitic announces the launch of an innovative feature to its platform, one which allows its customers to plot the geographic location of active clinical trials into […]
April 21, 2020

Cancer Care in the Time of Covid-19

While it seems much of our world has come to a halt since the spread of #covid19 , cancer continues to affect the lives of many. […]
April 21, 2020

Kognitic Launches Covid-19 Insight Series

With over 1 million globally confirmed Covid-19 cases, the promise of bringing lives back to ‘normal’ seems ambiguous. Amidst several strategies to fight against the disease, […]
April 21, 2020

University of Penn Has Done It Again!

University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which […]
April 21, 2020

Don’t Get Blindsided by Emerging Targets

Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they […]